Previous 10 |
Gossamer Bio, Inc. (GOSS) Q1 2019 Results Earnings Conference Call May 14, 2019, 08:30 AM ET Company Participants Bryan Giraudo - CFO Sheila Gujrathi - Co-Founder and CEO Conference Call Participants Ying Huang - Bank of America/Merrill Lynch Joseph Schwartz - SVB Leerink ...
Gossamer Bio (NASDAQ: GOSS ): Q1 GAAP EPS of -$0.90 misses by $0.24 . More news on: Gossamer Bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– Multiple trial initiations and data readouts expected in the next 12 months – – Company to host conference call today at 8:30 a.m. ET – Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring,...
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2019 financial...
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced it entered into a five-year senior debt facility led by...
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 17:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for GOSS on June 24, 2024 04:04PM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.8261 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...